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ABSTRACT
Objective: To determine the health-care resource use and
costs attributable to treating atrial ﬁbrillation (AF) in the
United States.
Methods: Retrospective analyses of three federally funded
US databases (2001 data): 1) hospital inpatient stays (the
Healthcare Cost and Utilization Project [HCUP]); 2) physi-
cian ofﬁce visits (the National Ambulatory Medical Care
Survey [NAMCS]); and 3) emergency department (ED) and
hospital outpatient department visits (OPD) (the National
Hospital Ambulatory Medical Care Survey [NHAMCS]).
Identiﬁcation of AF medical encounters was based on occur-
rence of AF-speciﬁc International Classiﬁcation of Diseases
(9th Edition)—Clinical Modiﬁcation (ICD-9-CM) diagnosis
code 427.31 (principal discharge diagnosis for inpatient set-
ting; any diagnosis ﬁeld for other settings). For the 10 most
common principal discharge diagnoses in the inpatient set-
ting, case–control comparison analyses were performed to
estimate annual incremental costs of AF as a comorbid dis-
charge diagnosis for hospital stays. Regression models were
used to assess the impact of AF on hospitalization costs.
Costs were estimated in year 2005 US dollars.
Results: Approximately 350,000 hospitalizations, 5.0 mil-
lion ofﬁce visits, 276,000 ED visits, and 234,000 OPD were
attributable to AF annually within the United States. Total
annual costs for treatment of AF were estimated at $6.65 bil-
lion, including $2.93 billion (44%) for hospitalizations with
a principal discharge diagnosis of AF, $1.95 billion (29%) for
the incremental inpatient cost of AF as a comorbid diagnosis,
$1.53 billion (23%) for outpatient treatment of AF, and
$235 million (4%) for prescription drugs. In all regressions,
AF was a signiﬁcant contributor to hospital cost.
Conclusions: Treatment of AF represents a signiﬁcant
health-care burden with the costs of treating AF in the inpa-
tient setting outweighing the costs of treating AF in the ofﬁce,
emergency room or hospital outpatient settings. Further
research is needed to fully capture the costs of treating AF.
Keywords: atrial ﬁbrillation, cost, resource use, retrospective
study.
Introduction
Atrial ﬁbrillation (AF), the most common sustained
cardiac arrhythmia encountered, currently affects
approximately 2.2 million people in the United States
[1] and increases in prevalence with age. Given the
impending increase in the elderly population, AF is
anticipated to become an increasing burden on the
health-care system with Go et al. [2] estimating a 2.5-
fold increase in number of patients with AF over the
next 50 years. Nevertheless, despite the high preva-
lence of AF, little has been done to evaluate the overall
economic burden of this disease. The majority of the
economic studies on AF have been conducted in the
United States with a hospital or third-party payer per-
spective using decision modeling to estimate the costs
of speciﬁc treatments. These studies focused speciﬁ-
cally on costs associated with either interventional pro-
cedures [3–6], anticoagulation and stroke prevention
[7–13], or pharmacological treatments [3,7–10,12,14–
17]. Studies examining the “national” cost of AF have
been conducted in the UK [18] and France [12], how-
ever, the overall cost of treating AF in various health-
care settings has not been examined in the United
States. As such, the objective of this study was to deter-
mine the impact of AF on health-care resource use and
costs in the hospital inpatient, outpatient, and ofﬁce
visit settings in the United States.
Methods
Data Sources
Three separate, cross-sectional, federally funded, and
nationally representative medical encounter databases
were analyzed, including: 1) The Healthcare Cost and
Utilization Project’s (HCUP) Nationwide Inpatient
Sample database (2001); 2) The National Ambulatory
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Medical Care Survey (NAMCS) database (2001); and
3) The National Hospital Ambulatory Medical Care
Survey (NHAMCS) database (2001). HCUP contains
hospital discharge data from a 20% sample of US hos-
pitals. The hospital sampling frame is deﬁned as com-
munity hospitals (including public hospitals, academic
medical centers and specialty hospitals) that were open
during any part of 2001. Each hospital stay record
contains: patient age, sex, principal and comorbid dis-
charge diagnoses, medical or surgical procedures/tests,
length of stay, and total billed charges. Fees for physi-
cian services are not included in HCUP.
NAMCS contains annual physician ofﬁce visit data
from an approximate 0.3% sample of US physician
ofﬁces. Each visit record includes: age, sex, up to three
listed diagnoses, drugs prescribed, and diagnostic and
medical or surgical procedures/tests performed during
the visit. NHAMCS contains annual emergency room
(ER) and hospital outpatient department (OPD) visit
data from an approximate 10% sample of US short-
stay (average length of stay [LOS] < 30 days) hospi-
tals. NHAMCS variables are similar to those included
in NAMCS.
For each database, each of the discharge or visit
records in the databases contains a weighting variable
that was utilized in analyses to provide nationally rep-
resentative estimates.
Identiﬁcation of AF-Related Medical Encounters
Identiﬁcation of AF-related encounters in the inpatient
setting was based on the designation of the Interna-
tional Classiﬁcation of Diseases (9th Edition)—Clini-
cal Modiﬁcation (ICD-9-CM) diagnosis code 427.31
(atrial ﬁbrillation) as either the principal or comorbid
discharge diagnosis. Hospitalizations with a valvular-
related diagnosis (ICD-9-CM 093.20, 394.0, 424.0,
746.3) were excluded from this analysis.
For the NAMCS/NHAMCS analyses, a visit record
qualiﬁed as AF-related by one of four ways: 1) the AF
diagnosis code was the only listed code on the record;
2) the AF diagnosis code was listed among other codes,
but one of the “reason for visit” codes included cardi-
ovascular disease; 3) a drug used to treat AF was
prescribed; or 4) a procedure related to AF was
performed.
Inpatient Costs of AF
The economic perspective was that of a third-party
payer. HCUP provides information on total billed
charges, excluding physician fees, for a given discharge
but not the actual costs of providing services, which
more closely relates to the amount reimbursed by pay-
ers. Hospital-speciﬁc cost-to-charge ratios are not pro-
vided therefore an average cost-to-charge ratio of 0.53,
estimated from publicly available Medicare Cost
Report Data for 2001 [19], was applied to the total
billed charges. The cost estimates based on 2001 data
were updated to year 2005 US dollars based on the
Consumer Price Index for hospital inpatient services
(conversion factor of 1.275 to adjust 2001 to 2005
dollars) [20].
The cost estimate for AF in the inpatient setting
includes two principal components: 1) costs due to AF
as a principal discharge diagnosis; and 2) costs attrib-
utable to AF as a secondary (comorbid) discharge diag-
nosis. For the ﬁrst component, the full costs of
hospitalizations with a principal discharge diagnosis of
AF were attributed to AF. Costs for inpatient physician
services were estimated based on Medicare’s National
Average Allowance for speciﬁc evaluation and man-
agement service codes for 2005 [21]. Code 99211 was
applied to the initial day of hospitalization, code
99238 to the day of discharge, and code 99231 for all
days in between.
For the second component, a case–control compar-
ison was utilized to estimate the “incremental” eco-
nomic impact of AF. This analysis focused on the 10
most common principal discharge diagnoses in HCUP
with AF as a comorbid diagnosis (Table 1). Hospital-
izations with one of the 10 principal discharge
Table 1 Top 10 HCUP diagnoses with atrial ﬁbrillation as a comorbid diagnosis (2001)
Primary diagnosis
Total
count*
Count
with AF Percent
No. per
group
Mean age
(SD)
Proportion
female (%)
Proportion
white (%)
428.0—CONGESTIVE HEART FAILURE 803,606 221,201 31.5 33,289 77.3 (10.7) 51.7 85.0
486—PNEUMONIA, ORGANISM NOS 773,994 114,200 15.8 16,707 79.9 (9.8) 50.9 90.1
414.01—CRNRY ATHRSCL NATVE VSSL 1008,625 105,980 15.1 16,295 71.7 (9.5) 34.5 88.6
410.71—SUBENDO INFARCT, INITIAL 334,746 55,160 7.8 8,364 76.3 (10.3) 44.5 88.8
491.21—OBS CHR BRNC W ACT EXA 484,393 50,064 7.1 7,633 75.8 (9.1) 48.9 90.8
434.91—CRBL ART OCL NOS W INFRC 226,596 34,576 4.9 5,176 79.7 (9.0) 61.2 86.4
276.5—HYPOVOLEMIA 384,545 33,403 4.8 4,919 81.1 (9.3) 61.5 88.3
507.0—FOOD/VOMIT PNEUMONITIS 173,539 30,597 4.4 4,594 82.8 (8.5) 43.5 89.2
427.81—SINOATRIAL NODE DYSFUNCT 74,166 30,318 4.3 4,525 77.9 (8.6) 52.3 92.5
599.0—URIN TRACT INFECTION NOS† 273,783 29,078 4.1 4,359 82.3 (8.4) 66.3 87.2
*The sample discharges for each diagnosis were weighted to be nationally representative based on the discharge-level weights provided in the Healthcare Cost and Utilization
Project (HCUP).
†The primary diagnosis “V578.9—Rehabilitation procedures” (number 6 in frequency) was not included in this analysis because of the heterogeneity of this diagnosis. To com-
pensate, diagnosis “599.0—Urinary tract infection” (number 11 in frequency) was included in the analysis.
Source. 2001 HCUP.
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diagnoses and a comorbid diagnosis of AF, were sep-
arated into 10 distinct “case” groups based on the
principal discharge diagnosis. Controls for each spe-
ciﬁc principal discharge diagnosis were selected from
the pool of hospitalizations that did not include a
comorbid diagnosis of AF. Each case was matched to a
control on the following variables: age, sex, race, prin-
cipal discharge diagnosis, and bed size category of hos-
pital (i.e., large, medium, small).
Outpatient Costs of AF
Neither costs nor charges are reported in NAMCS/
NHAMCS; thus, to estimate the costs associated with
AF-related visits, the resource use items (i.e., drugs,
procedures) recorded were assigned unit costs and then
summary costs calculated.
The NAMCS ofﬁce visit records include the amount
of time the patient spends with the doctor. This time
was averaged for all AF visits, and the appropriate eval-
uation and management Current Procedural Terminol-
ogy (CPT) code was assigned. For physician fees for the
emergency department (ED) and OPD settings, the
lowest level of visit complexity was assumed in each
setting to provide the most conservative cost estimate.
The unit costs for the chosen CPT codes were based on
national prevailing fees for 2004 [21], updated to year
2005 US dollars based on the Consumer Price Index for
hospital outpatient services (conversion factor of 1.05
for the period between 2004 and 2005) [22].
Each visit record includes up to a maximum of six
medications that were prescribed during the visit. The
medication name is reported, but not the days supplied
or daily dose. Therefore, each drug was assigned an esti-
mated “days supplied” and “daily dose” amount based
on drug-speciﬁc recommendations in the Physician’s
Desk Reference (PDR). The default value for days sup-
plied was “30” for the ofﬁce or OPD setting and “1”
for the ER setting if the PDR did not specify a length of
therapy. Drug costs were estimated based on the aver-
age wholesale price reported in the 2004 Drug Topics
RED BOOK, updated to year 2005 US dollars based on
the Consumer Price Index for prescription drugs (con-
version factor of 1.05 for the period between 2004 and
2005) [23]. Oral intake was assumed for all estimated
drug costs. The cost analysis included only drugs used
to treat AF, as determined by a review of all recorded
medications by two expert clinicians.
Facility costs (for ED and OPD settings) were esti-
mated based on publicly available claims data utilized
by the CMS to develop the Outpatient Prospective
Payment [24]. Facility costs were updated to 2005
using the Consumer Price Index for hospital outpatient
services [22].
Statistical Analyses
All statistical analyses were conducted using SAS
(Release 8.02; SAS Institute Inc., Cary, NC, USA).
Where appropriate for counts, frequency distributions
or means, the weight variables in the databases were
utilized to provide accurate national estimates.
Because of the large sample sizes, statistical tests were
considered signiﬁcant at P < 0.001. Nonparametric
Wilcoxon rank sum tests were used to test for statis-
tical signiﬁcance due to non-normal data distributions
[25].
An ordinary least squares (OLS) regression model
was used to assess the contribution of certain factors
in predicting total charges for AF hospitalizations.
Charges were transformed into logarithms due to
skewed distributions (i.e., long tails of expensive hos-
pitalizations). The regression model included: age, sex,
race, expected primary payer, bed size of hospital,
emergency admission, surgery performed not related
to principal discharge diagnosis (based on record of
any surgical diagnosis-related groups), and comorbid-
ities (yes/no for each of 30 comorbidity variables
developed and validated by Elixhauser et al. [26] for
use in predicting costs with administrative data; for all
models, the comorbidity of cardiac arrhythmias was
excluded).
OLS regression models were also used in the case–
control comparison to assess the incremental cost of
AF on total charges for each of the 10 case–control
matches. The model structure was the same as
described in the above paragraph except for the addi-
tion of the case–control status variable. To allow for a
direct interpretation (i.e., in dollar terms) of the
parameter estimates from the log-transformed models,
a “smearing” or retransformation factor was applied
to each regression model [27]. Once the incremental
charges per hospitalization due to AF were estimated
for each of the 10 principal discharge diagnoses, the
charges were converted to costs and then multiplied
against the annual number of hospitalizations in the
United States that included the respective principal
diagnoses and a comorbid diagnosis of AF.
Results
Inpatient Analyses
There were an estimated 348,131 hospitalizations in
the United States in the year 2001 with AF listed as the
principal discharge diagnosis. Consistent with the epi-
demiology of AF, the majority of hospitalizations
involved patients ages 65 years and older (72%), with
13% ages 85 and older. Approximately 54% of the AF
hospitalizations involved female patients and a large
majority (88%) involved white patients. The most fre-
quent comorbid conditions for patients hospitalized
with a primary diagnosis of AF were hypertension
(36%), congestive heart failure (CHF) (19%), coro-
nary atherosclerosis (18%), and chronic obstructive
pulmonary disease (COPD) (10%). Echocardiography
was the most commonly performed procedure during
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hospitalizations with AF as a primary diagnosis
(occurring during 9% of AF hospitalizations).
AF as a primary diagnosis in the inpatient setting
resulted in an estimated $2.93 billion (year 2005 US
dollars) in direct medical costs (Table 2). The mean
(± SE) costs per AF hospital stay were $8412 ± 230,
and the mean (± SE) LOS was 3.6 ± 0.04. The mean
(± SE) costs for AF hospital stays involving either cath-
eter ablation or cardiac mapping were substantially
higher at $23,080 ± 2613. For the top 10 discharge
diagnoses in HCUP, the proportion of hospitalizations
with AF as a comorbid diagnosis ranged from 31.5%
in patients with CHF to 4.1% in patients with a uri-
nary tract infection (UTI) (Table 1).
Table 3  presents estimates of the incremental eco-
nomic impact of AF as a comorbid diagnosis. For all
10 diagnoses in Table 3 combined, the total annual
incremental impact of AF as a comorbid diagnosis in
the inpatient setting was estimated at $1.95 billion.
This ﬁgure is conservative given that there were an
additional 1.6 million hospitalizations with AF as a
comorbid discharge diagnosis not among the top 10
HCUP diagnoses.
Table 4 summarizes the results of the OLS regres-
sions used to calculate the incremental cost impact of
AF reported in Table 3. The independent variables
included in the 10 separate regression models are listed
in the ﬁrst column, and the 10 principal discharge
diagnoses of interest are listed in the top row. The “+”
symbol represents when the parameter estimate for a
given variable was statistically signiﬁcant at P < 0.001,
and the parameter estimate had a positive impact on
total charges. The “–” symbol represents when the
parameter estimate was statistically signiﬁcant at
P < 0.001, and had a negative impact on total charges.
For example, the variable representing the presence of
AF as a secondary diagnosis (“Case”) was statistically
signiﬁcant in all 10 regressions, and was associated
Table 2 Number of atrial ﬁbrillation (AF) hospitalizations, average length of stay, average costs per stay, and total costs, 2001 
Description Sample N
National
estimate*
Length of stay (days) Average costs (year 2005 $)† Total annual costs
(year 2005 $)†,‡Mean SE Median Mean SE Median
Principal discharge diagnosis of
AF (427.31)
69,678 348,131 3.59 0.04 3.00 8,412 230 5,123 2928.5
Principal discharge diagnosis of
AF and catheter ablation or 
cardiac mapping
1,676 8,526 3.50 0.16 2.00 23,080 2613 18,228 197.4
Principal discharge diagnosis of
AF and atrial cardioversion
4,744 23,851 3.43 0.11 3.00 7,873 473 4,425 188
*The number of estimated annual hospitalizations for each query once the HCUP weighting scheme is applied. As a point of reference, there were a total of 37.2 million hos-
pitalizations in the United States in 2001 per HCUP.
†Updated to year 2005 US dollars based on the Hospital Inpatient Services Component of the Consumer Price Index (conversion factor of 1.275 between 2001 and 2005). The
dollars reported are in millions—for example, $2856.2 million equates to $2,856,200,000.
‡Average billed charges converted to costs (in millions) based on national average hospital cost-to-charge ratio of 0.53, estimated based on publicly available Medicare Cost
Report Data.
ICD-9-CM procedure codes: 37.34 (catheter ablation of lesion or tissues of heart); 37.27 (cardiac mapping); 99.61 (atrial cardioversion).
Source. 2001 HCUP.
Table 3 Incremental impact of comorbid atrial ﬁbrillation (AF): results of case–control analysis
Principal discharge diagnosis code
Incremental costs ($)*
due to AF per
hospitalization
(a)
Number of annual 
hospitalizations with 
principal discharge 
diagnosis code, and 
secondary AF diagnosis†
(b)
Incremental costs ($) 
due to AF on
annual basis 
(a) × (b)
428.0—Congestive heart failure 1,682 221,201 372,060,082
486.0—Pneumonia 1,761 111,775 196,835,775
414.01—Coronary atherosclerosis native vessel 7,286 105,980 772,170,280
410.71—Acute myocardial infarction, subendocardial 4,422 55,160 243,917,520
491.21—COPD 2,136 50,064 106,936,704
434.91—Cerebral artery occlusion, unspeciﬁed, with infarction 2,195 34,576 75,894,320
276.5—Hypovolemia 1,091 33,403 36,442,673
507.0—Food/vomit pneumonitis 2,339 30,597 71,566,383
427.81—Sinoatrial node dysfunction 1,051 30,318 31,864,218
599.0—Urinary tract infection 1,324 29,078 38,499,272
1,946,187,227
*Average billed charges converted to costs (in millions) based on national average hospital cost-to-charge ratio of 0.53, estimated based on publicly available Medicare Cost
Report Data. Updated to year 2005 US dollars based on the Hospital Inpatient Services Component of the Consumer Price Index (conversion factor of 1.275 between 2001
and 2005).
†The number of estimated annual hospitalizations for each query once the HCUP weighting scheme is applied. As a point of reference, there were a total of 37.2 million hos-
pitalizations in the United States in 2001 per HCUP.
Source. 2001 HCUP.
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with an increase in total charges. Other interesting
ﬁndings included:
• Increased age was associated with lower total
charges for 7 of the 10 regression models.
• Being female was associated with lower total
charges when the principal discharge diagnosis
was either acute myocardial infarction (MI) or
coronary atherosclerosis, but was associated with
higher total charges when the principal discharge
diagnosis was either pneumonia or COPD.
• White patients had signiﬁcantly lower total
charges (relative to nonwhite patients) in all 10
regression models.
• An emergency admission was associated with
increased total charges in all but two of the regres-
sion models (i.e., acute MI and coronary athero-
sclerosis).
• CHF as a comorbid diagnosis was associated with
increased  total  charges  in  all  but  two regres-
sion models (sinoatrial node dysfunction and
pneumonia).
• COPD as a comorbid diagnosis was associated
with increased total charges in all regression
models.
Outpatient Analyses
As with the inpatient setting, the majority of patients
were 65 years or older, with a substantial proportion
over the age of 75 years (Table 5). There were an esti-
mated 5.0 million AF-related ofﬁce visits, 276,000 AF-
Table 4 OLS Regressions with Total Charges as Dependent Variable
ICD-9-CM Diagnosis Code 276.5 410.71 414.01 427.81 428.0 434.91 486 491.21 507.0 599.0
Adjusted R2 0.1244 0.15 0.1627 0.0331 0.0995 0.1636 0.1638 0.1413 0.1351 0.1537
Independent variable
Case + + + + + + + + + +
Age + – – – – – – –
Female – – + +
White – – – – – – – – – –
Medium bed size hospital + + + + + + + + + +
Large bed size hospital + + + + + + + + + +
Medicare – – + –
Medicaid
Self pay – – –
Other insurance – – –
Emergency admit + – – + + + + + + +
Occurrence of surgical DRG + + + + + + + + +
CABG + +
Comorbidity variables
CHF + + + + + + +
Cardiac arrhythmias + +
Pulmonary circulation disorders +
Peripheral vascular disorders + +
Hypertension – –
Paralysis + + +
Other neurological disorders + + + + +
COPD + + + + + + + + +
Diabetes, uncomplicated
Diabetes, complicated +
Hypothyroidism
Renal failure + + +
Liver disease + +
Peptic ulcer disease +
AIDS
Lymphoma
Metastatic cancer + + +
Solid tumor without malignancy
Rheumatoid arthritis
Coagulopathy + + + + + + + + +
Obesity
Weight loss + + + + + +
Fluid/electrolyte disorders + + + + + + + +
Blood loss anemia + + + + + +
Deﬁciency anemias + + + + + + + +
Alcohol abuse
Drug abuse
Psychoses +
Depression –
 = variable excluded from regression;  = zero patients had comorbidity; + represents when P < 0.001 and parameter estimate had positive impact on charges;
– represents when P < 0.001 and parameter estimate had negative impact on charges.
CABG, Coronary Artery Bypass Graft; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; DRG, diagnosis-related groups; ICD-9-CM, International
Classiﬁcation of Diseases (9th Edition)—Clinical Modiﬁcation.
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related ED visits and 234,000 AF-related OPD visits in
2001 (Table 5). Total annual direct medical costs for
the ambulatory/outpatient treatment of AF were esti-
mated at $1.76 billion (year 2005 US dollars) with
ofﬁce visits accounting for 66.2% of costs, and the
remainder being split among ED visits (17.4%) and
hospital OPD visits (16.4%). Drug costs accounted for
19.1% of ofﬁce visit costs, 0.5% of ER costs, and
3.5% of OPD costs.
Cost of AF
Total annual medical costs for the treatment of AF in
the inpatient, ER and hospital outpatient settings in
the United States were estimated at $6.65 billion (year
2005 US dollars). This estimate includes costs for all
hospitalizations where AF (427.31) was the principal
discharge diagnosis ($2.93 billion), the incremental
inpatient costs due to AF as a comorbid diagnosis
(conservatively estimated at $1.95 billion), and costs
for all ambulatory/outpatient treatment of AF ($1.76
billion) (Fig. 1).
Table 5 Cost and distribution of atrial ﬁbrillation-related* visits to doctor’s ofﬁce, ED and OPD, 2001
Characteristic Doctor’s ofﬁce (%) ED (%) OPD (%)
Number of visits
Sample count 175  65  67
Count weighted† (a) 4,959,552 275,537 233,637
Average $ per encounter (b) 235 1,111 1,241
Physician‡ 135  80  135
Tests and procedures‡ 55 1,025 1,062
Drugs‡ 45  6  44
Total $ (in millions)§ (a) × (b)  1,165.5  306.1  289.9
Age category (years)
≤44 1.6  5.9  0.4
45–64 11.6  19.6  30.3
65–74 30.5  19.0  22.4
≥75 56.3  55.5  46.9
Sex (% female) 47.3  54.9  49.2
Race
White 93.1  86.8  84.0
African American 4.8  11.8  14.6
Hispanic 2.1  1.5  1.2
Other 0.0  0.0  0.2
Most common AF-related 
prescriptions||
Coumadin (41%)
Digoxin (29%)
Diltiazem (28%)
Digoxin (21%)
Coumadin (46%)
Digoxin (31%)
Atenolol (10%) Coumadin (11%) Toprol XL (17%)
Amiodarone (6%) Sotalol (3.9%) Flecainide (2.7%)
Most common AF-related 
tests/procedures||
Diagnostic 
ultrasound 
heart (1.2%)
Arterial blood gas 
measure (24%)
Cardiac stress 
test (71%)
DC cardioversion 
(1.0%)
DC cardioversion 
(18%)
DC cardioversion 
(3%)
Cardiac stress 
test (0.9%)
Cardiac stress 
test (15%)
*Based on occurrence of ICD-9-CM diagnosis code 427.31 in any diagnosis ﬁeld.
†National estimate based on applying visit weights to qualifying sample visits.
‡Physician fee assigned based on the 2004 Physicians Fee & Coding Guide (A Comprehensive Fee & Coding Reference); HealthCare Consultants of America, Inc., Augusta (GA).
Tests and procedure costs were obtained from CMS’s Ambulatory Payment Classiﬁcation System (APC). Drug costs were obtained from Drug Topics RED BOOK 2004, updated
to year 2005 US dollars based on the Consumer Price Index for prescription drugs (conversion factor of 1.05 for the period between 2004 and 2005).
§Calculated by multiplying average $ per encounter by number of annual encounters.
||Proportion of visits with occurrence of AF-related drug or procedure
Sources: 2001 NAMCS, 2001 NHAMCS.
AF, atrial ﬁbrillation; DC, direct current; ED, emergency department; OPD, outpatient department.
Figure 1 Distribution of inpatient and selected outpatient costs for
treating atrial ﬁbrillation.
Direct Inpatient, 44%
Indirect Inpatient, 29%
Outpatient, 23%
Drugs, 4%
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Discussion
This study provides an overall estimate of the direct
treatment costs associated with AF across inpatient
and various outpatient treatment settings and exam-
ines the incremental cost of AF as a comorbid diagno-
sis. Although the cost of AF is substantial, this estimate
is conservative as not all encounters with AF as a
comorbidity were included in this analysis. Impor-
tantly, the presence of AF increases inpatient costs of
patients with both cardiovascular and noncardiovas-
cular (e.g., pneumonia, UTI, COPD) diseases. These
ﬁndings are similar to those noted by Wolf et al. [28]
who used Medicare hospital claims and MedPAR data
to compare costs and outcomes of patients with AF
versus patients without AF; the patients with AF
incurred higher costs and experienced a 20% higher
mortality rate than patients without AF.
Our ﬁndings are also similar to those noted in
Dell’Orfano et al.’s [29] retrospective analysis of hos-
pital records to determine the costs of care for an acute
treatment of AF in the United States. Hospital charges
were highest for the group requiring direct current car-
dioversion ($9892); patients who spontaneously con-
verted had the lowest hospital charges of $4930. In
our analysis, the cost for hospitalization with a direct
current cardioversion was $7873. The cost for a cath-
eter ablation and/or cardiac mapping was much higher
at $23,080. Clearly, more aggressive procedures result
in higher costs.
To provide context for the costs of AF compared
with other cardiovascular illnesses, the total direct
costs for all cardiovascular disease are estimated at
$242 billion annually in the United States with CHF
accounting for $25 billion and stroke $35 billion [30].
These estimates also include the costs of nursing home
and home health care, which were not part of our
analysis.
Although costs for procedures were captured in our
analysis, the cost of long-term anticoagulation and
stroke prevention per se was not captured in this anal-
ysis because it was beyond the scope of our analysis.
The cost of stroke prevention has been previously well
analyzed [7–11] with Menzin et al. [31] reporting the
average costs for one full year of anticoagulation to be
about $300 and Anderson et al. [32] ﬁnding the
annual anticoagulation costs to be $600. The outpa-
tient analysis examined drug costs; however, duration
of treatment was estimated. Although drug charges are
included in HCUP costs, the actual drug and treatment
regimen cannot be discerned; thus inpatient drug costs
could not be analyzed. As such, the estimated cost of
AF of $6.65 billion per year is underestimated as the
cost for stroke prevention treatments, inpatient drug
costs, remaining encounters with AF as a comorbid
condition, and inpatient physician fees are not
included. Additionally, indirect costs of AF (e.g., work
loss, reduced leisure time, quality-of-life impact),
which are likely to be signiﬁcant, could not be assessed
in this analysis.
The racial disparity noted in our study is similar to
that noted by Baine et al. [33] in an analysis of Medi-
care beneﬁciaries with a higher prevalence of white
men and women being hospitalized with AF than other
races. Using National Hospital Discharge Survey
records, Khairallah et al. [34] found 71.5% of the
population to be white, 5.6% to be African American
and 20.8% to be “not speciﬁed.” Approximately 88%
of the primary AF diagnoses group was white com-
pared with a proportion of 69% white for all US hos-
pitalizations in 2001 [35]. The cause of this racial
variation would be interesting to explore because it is
not known whether this is related to the epidemiology
of the disease or barriers to health care.
Studies in the United States and other countries
have found that the number of hospitalizations for AF
has increased substantially in recent years [36–39].
This could be due to a true increase in AF prevalence,
changes in how AF is recorded or coded as a diagnosis,
or both.
There are a number of limitations associated with
this cross-sectional analysis. First, the HCUP billed
charges data do not include fees for hospital-based
physician services. To be conservative, the analysis did
not attempt to estimate these costs. Second, neither the
HCUP nor NAMCS/NHAMCS databases included the
actual costs of care for reported services. An average
charge-to-cost ratio was applied uniformly across
all discharges, and this could either overestimate or
underestimate the actual costs of care at a given insti-
tution. Third, the study utilized cross-sectional data
that did not allow for a longitudinal tracking of
patients and their full episodes of care for AF-related
illness. In addition, the lack of longitudinal data
limited the ability of the study to identify all patient
comorbidities, because only the comorbidities listed on
the selected visits could be captured for the analyses.
Lastly, the cost of AF as a comorbid condition was
only captured for 10 HCUP diagnoses leaving the
incremental cost associated with 1.6 million other hos-
pitalizations not known. As such, the estimates pre-
sented here are conservative.
As the prevalence of AF increases with age, AF is
anticipated to become an increasing burden on the
health-care system. Future research should consider
possible areas of reducing costs such as those demon-
strated by Zimetbaum et al. [40], where practice
guidelines on treating AF were instituted in the ED.
These guidelines reduced the hospital admission rate
from 74% to 38% without affecting clinical outcomes.
Such interventions could have a tremendous ﬁnancial
impact in reducing the cost of AF.
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Source of ﬁnancial support: Funding for this project was pro-
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